左西孟旦联合米力农治疗重度心力衰竭的临床效果与安全性  

The clinical efficacy and safety of combined levosimendan and milrinone therapy in severe heart failure

作　　者：杨帆 朱万荣 刘成华 于海亮 YANG Fan;ZHU Wanrong;LIU Chenghua;YU Hailiang(Linyi Central Hospital,Shandong Province,Linyi 276400,China)

机构地区：[1]山东省临沂市中心医院,276400

出　　处：《临床合理用药杂志》2024年第7期29-32,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察左西孟旦联合米力农治疗重度心力衰竭的临床效果与安全性。方法回顾性分析2021年1—12月临沂市中心医院收治的90例重度心力衰竭患者临床病例资料,根据治疗方案不同分为观察组和对照组,各45例。在常规治疗基础上,对照组予米力农注射液治疗,观察组予左西孟旦注射液联合米力农注射液治疗,2组均治疗5 d。比较2组患者治疗效果,治疗前后心功能指标[左室舒张末期内径(LVEDD)、左室射血分数(LVEF)]、生化指标[N末端B型利钠肽原(NT-proBNP)、超敏C反应蛋白(hs-CRP)]及不良反应。结果观察组与对照组治疗总有效率比较差异无统计学意义(91.1%vs.82.2%,χ^(2)=1.538,P=0.215)。治疗5 d后,2组LVEDD较治疗前缩小,LVEF较治疗前升高,且观察组缩小/升高幅度大于对照组(P<0.05或P<0.01);2组NT-proBNP、hs-CRP水平较治疗前降低,且观察组低于对照组(P均<0.01)。观察组与对照组不良反应总发生率比较差异无统计学意义(13.3%vs.11.1%,χ^(2)=0.104,P=0.748)。结论左西孟旦联合米力农治疗重度心力衰竭的临床效果肯定,能够积极改善患者相关心功能指标与生化指标,且安全性较高。Objective To observe the clinical efficacy and safety of combined levosimendan and milrinone therapy in severe heart failure.Methods A retrospective analysis was conducted on the clinical records of 90 severe heart failure patients admitted to Linyi Central Hospital from January to December 2021.Based on different treatment regimens,the patients were divided into an observation group and a control group,with 45 cases in each group.In addition to conventional treatment,the control group received milrinone injection,while the observation group received combined treatment with levosimendan injection and milrinone injection.Both groups were treated for 5 days.The treatment effects,changes in cardiac functional indicators(LVEDD,LVEF),biochemical indicators(NT-proBNP,hs-CRP)before and after treatment,as well as the occurrence of adverse reactions in the two groups were compared.Results There was no statistically significant difference in the comparison of the total effective rate between the observation group and the control group(91.1%vs.82.2%,χ^(2)=1.538,P=0.215).After 5 days of treatment,both groups showed a reduction in LVEDD and an increase in LVEF compared to before treatment,and the magnitude of reduction or increase in the observation group was greater than that in the control group(P<0.05 or P<0.01).The levels of NT-proBNP and hs-CRP in both groups decreased compared to before treatment,and the levels in the observation group were lower than those in the control group(P<0.01).There was no statistically significant difference in the comparison of the overall incidence of adverse reactions between the observation group and the control group(13.3%vs.11.1%,χ^(2)=0.104,P=0.748).Conclusion The clinical efficacy of combined levosimendan and milrinone therapy in severe heart failure is worthy of recognition,as it can actively improve patients′cardiac functional indicators and biochemical markers,with a high level of safety.

关 键 词：重度心力衰竭 左西孟旦 米力农 心功能 生化指标 安全性 

分 类 号：R541.6[医药卫生—心血管疾病]